(COMTEX) A: New twist on ADHD drug makes it last
A: New twist on ADHD drug makes it last
BOSTON, Aug 05, 2002 (United Press International via COMTEX) -- A reformulated
and longer-lasting drug helps children with attention deficit hyperactivity
disorder who struggle to comply with their current treatment schedules, a new
study announced Monday reveals.
Researchers led by Dr. Joseph Biederman, director of pediatric
psycholopharmacology at Massachusetts General Hospital found a newer formulation
of the stimulant Adderall, taken only once a day in the morning, provided
effective treatment of ADHD symptoms throughout the entire day.
"This medication provides continuous medication support and treatment of ADHD,"
Biederman told United Press International. Not only were children able to get
through the school day without problems, he said, but their treatment also
continued to be effective after school, when children often are playing sports
or active in after-school activities.
The study, funded by Adderall's manufacturer, Shire Pharmaceuticals of
Hampshire, England, looked at more than 500 children ages 6 to 12 who had been
diagnosed with ADHD. The children were located in 47 sites across the United
States. All were divided randomly into four groups.
For one week, all participants took a placebo to rinse their bodies of current
treatments. Then the children were placed into one of the four groups. One group
stayed on placebo therapy from start to finish. The remaining three were placed
on a 10-milligram-daily dose of the newer Adderall formulation. After one week,
two of the three medicated groups starting receiving 20 milligrams per day.
Following one week of that therapy, one of the two groups advanced to a
30-milligram-daily dosage. The study was double-blinded so no one among the
children, their parents and researchers knew what dosages participants took.
During the four-week study, the children received weekly evaluations from their
physicians. Also, parents and teachers completed weekly evaluations of the
children's behavior at home and at school. All the children also underwent
complete physical examinations before and after the study.
The study results showed even the 10 milligram dosage produced significant
behavioral improvements throughout the day and into the evening when compared to
children on placebo. Symptom improvements registered with each dosage increase,
researchers report, with children on the 30 milligram dosage receiving the best
evaluations from both teachers and parents. No serious side effects were
observed.
The latest formulation of Adderall provides steady relief while minimizing
interruption during the child's day at school and afterward. Earlier treatments
of ADHD required children to go to the school nurse to receive their
medications, but Biederman said this newer therapy helps kids avoid being
publicly identified for having ADHD.
"Adderall is a very effective alternative to Ritalin," Biederman said. "It's not
like replacing one with the other." It just widens the treatment options for
children since one approach does not always fit everyone, he said.
Standard Adderall is composed of several amphetamine-based drugs, but it only
works for four hours. The new formulation is similar to other long-acting
stimulants, such as extended-release Ritalin, researchers explained.
Dr. Jerry Rushton, a pediatrician at the University of Michigan at Ann Arbor
prescribes ADHD treatment and said a longer-lasting medication would be
particularly appealing to older students with this condition.
"I don't see (this study) as a major breakthrough," Rushton told UPI, but "I
can't emphasize how important it is especially for high schoolers and middle
schoolers who don't want to go down to the school nurse and be singled out."
The study is published in the August issue of Pediatrics, the journal of the
American Academy of Pediatrics.
(Reported by Katrina Woznicki, UPI Science News, in Washington)
Copyright 2002 by United Press International.
-0-
SUBJECT CODE: 04002006 07003000 07005000 07007000 07014002 13003000 1300600
13009000
*** end of story *** |
